Company intelligence / Profile preview
HanAll Biopharma
Seoul, South Koreahanall.com ↗
- Ownership
- Public · 009420
- Development stage
- Phase 3
01
Overview
HanAll has multiple programs in development, including HL161 (batoclimab) for autoimmune diseases, HL036 (tanfanercept) for dry eye disease, HL192 for Parkinson's disease, and HL186/HL187 for cancer. The company has both marketed drugs and pipeline candidates.
- Therapeutic areas
- OphthalmologyOncologyImmunologyNeurology
- Modalities
- Monoclonal antibodiesBiologics
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Harbour BioMedRoivant SciencesTurn BiotechDaewoong PharmaceuticalNurrOn Pharmaceuticals
04
Financials
- Market cap
- $1.3B
- Total revenue
- $114.6M
- Enterprise value
- $1.4B
Beyond the preview
Go deeper on HanAll Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HanAll Biopharma.